The Stanford Hodgkin's disease (HD) studies--an update

Abstract

Successive, prospective clinical trials for adults with HD have been conducted from 1962-1991. With approximately 75% of patients in continuous remission as a result of current therapy, attention may be focused on reducing treatment complications for the majority of patients and improving efficacy in selected, high risk populations. This overview will describe recently completed and ongoing clinical trials at Stanford University which address these therapeutic objectives.